Compile Data Set for Download or QSAR
Report error Found 83 Enz. Inhib. hit(s) with all data for entry = 8480
TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081196(US9475814, 13 | CHEMBL3422015 | US10065961, Compou...)
Affinity DataIC50: 2nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081198(US9475814, 24 | CHEMBL3422018 | US10065961, Compou...)
Affinity DataIC50: 2nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081196(US9475814, 13 | CHEMBL3422015 | US10065961, Compou...)
Affinity DataKi:  3nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251923(US9475814, 25 | BDBM272562 | US10683295, Compound ...)
Affinity DataIC50: 3nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251909(US9475814, 7 | US10065961, Compound 7 | US10683295...)
Affinity DataIC50: 3nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251923(US9475814, 25 | BDBM272562 | US10683295, Compound ...)
Affinity DataKi:  3nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251907(US9475814, 5 | US10065961, Compound 5 | US10683295...)
Affinity DataIC50: 3nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251909(US9475814, 7 | US10065961, Compound 7 | US10683295...)
Affinity DataKi:  4nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251907(US9475814, 5 | US10065961, Compound 5 | US10683295...)
Affinity DataKi:  5nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081399(US9475814, 19 | CHEMBL3422016 | US10065961, Compou...)
Affinity DataKi:  6nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataIC50: 7nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251918(US9475814, 17 | US10065961, Compound 17 | US106832...)
Affinity DataKi:  7nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251910(US9475814, 8 | US10065961, Compound 8 | US10683295...)
Affinity DataKi:  7nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251910(US9475814, 8 | US10065961, Compound 8 | US10683295...)
Affinity DataIC50: 7nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081399(US9475814, 19 | CHEMBL3422016 | US10065961, Compou...)
Affinity DataIC50: 8nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251916(US9475814, 15 | US10065961, Compound 15 | US106832...)
Affinity DataIC50: 9nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251919(US9475814, 18 | US10065961, Compound 18 | US106832...)
Affinity DataIC50: 10nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081293(US9475814, 30 | CHEMBL3422007 | US10065961, Compou...)
Affinity DataKi:  10nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251908(US9475814, 6 | US10065961, Compound 6 | US10683295...)
Affinity DataIC50: 10nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251920(US9475814, 20 | US10065961, Compound 20 | US106832...)
Affinity DataIC50: 11nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081293(US9475814, 30 | CHEMBL3422007 | US10065961, Compou...)
Affinity DataIC50: 11nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251916(US9475814, 15 | US10065961, Compound 15 | US106832...)
Affinity DataKi:  11nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251908(US9475814, 6 | US10065961, Compound 6 | US10683295...)
Affinity DataKi:  11nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251920(US9475814, 20 | US10065961, Compound 20 | US106832...)
Affinity DataKi:  12nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251924(US9475814, 26 | US10065961, Compound 26)
Affinity DataIC50: 12nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataIC50: 16nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081195(US9475814, 1 | CHEMBL3422010 | US10065961, Compoun...)
Affinity DataKi:  16nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataIC50: 18nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251927(US9475814, 29 | US10065961, Compound 29 | US106832...)
Affinity DataIC50: 18nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251911(US9475814, 9 | US10065961, Compound 9 | US10683295...)
Affinity DataIC50: 18nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251911(US9475814, 9 | US10065961, Compound 9 | US10683295...)
Affinity DataKi:  19nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251919(US9475814, 18 | US10065961, Compound 18 | US106832...)
Affinity DataKi:  20nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251912(US9475814, 10 | US10065961, Compound 10 | US106832...)
Affinity DataIC50: 20nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251922(US9475814, 22 | US10065961, Compound 22 | US106832...)
Affinity DataKi:  21nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251922(US9475814, 22 | US10065961, Compound 22 | US106832...)
Affinity DataIC50: 21nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251928(US9475814, 31 | US10065961, Compound 31 | US106832...)
Affinity DataKi:  22nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251927(US9475814, 29 | US10065961, Compound 29 | US106832...)
Affinity DataKi:  23nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251905(US9475814, 2 | US10065961, Compound 2 | US10683295...)
Affinity DataKi:  26nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251905(US9475814, 2 | US10065961, Compound 2 | US10683295...)
Affinity DataIC50: 28nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataKi:  29nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251917(US9475814, 16 | US10065961, Compound 16 | US109411...)
Affinity DataIC50: 30nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251917(US9475814, 16 | US10065961, Compound 16 | US109411...)
Affinity DataKi:  32nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM50081197(US9475814, 23 | CHEMBL3422017 | US10065961, Compou...)
Affinity DataIC50: 33nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251921(US9475814, 21 | US10065961, Compound 21 | US106832...)
Affinity DataIC50: 33nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataIC50: 34nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251912(US9475814, 10 | US10065961, Compound 10 | US106832...)
Affinity DataKi:  36nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251926(US9475814, 28 | US10065961, Compound 28 | US106832...)
Affinity DataIC50: 37nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251921(US9475814, 21 | US10065961, Compound 21 | US106832...)
Affinity DataKi:  38nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251915(US9475814, 14 | US10065961, Compound 14 | US106832...)
Affinity DataKi:  42nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Euroscreen

US Patent
LigandPNGBDBM251913(US9475814, 11 | US10065961, Compound 11 | US106832...)
Affinity DataKi:  44nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
US Patent

Displayed 1 to 50 (of 83 total ) | Next | Last >>
Jump to: